Everest Organics obtains KDMF approval for Rabeprazole Sodium API

18 Feb 2025 Evaluate

Everest Organics has obtained Korea Drug Master File (KDMF) approval for its Rabeprazole Sodium API in the Month of February 2025. The Rabeprazole Sodium API is primarily used to treat conditions related to excessive stomach acid production, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, as it acts as a proton pump inhibitor (PPI) by significantly reducing the amount of acid produced in the stomach; essentially helping to heal ulcers and alleviate symptoms like heartburn and acid reflux. The company is now able to export its Rabeprazole Sodium API to the South Korean market.  

Everest Organics carry the business of manufacturing of bulk drugs viz. Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Benzimadizole, etc., having its factory at Sadasivpet Medak District Hyderabad. 

Everest Organics Share Price

404.00 -11.25 (-2.71%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×